EquityBulls

Latest News

Keywords Selected: INE935A01035

Stock Report

U.S. FDA inspection at Glenmark Pharmaceuticals Ltd's Baddi, India Facility
Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India
Glenmark Pharmaceuticals recommends dividend of Rs. 2.50
Glenmark Pharma gets 5 observations from U.S. FDA for its Goa, India Facility
Glenmark Pharma gets 17 observations from U.S. FDA for its Monroe, North Carolina (USA) Facility
Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 500 mg
Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%, 0.064%
Glenmark receives the 'India Pharma Innovation of the Year' Award from the Government of India
Glenmark to launch Drug for Type 2 Diabetes in India
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276
Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg
Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules® in Columbia
Glenmark launches Nasal Spray for Covid19 treatment in India in partnership with SaNOtize
Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%
Glenmark receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP
Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement
Glenmark Pharma receives tentative ANDA approval for Regadenoson Injection
Glenmark Specialty S.A. gets NDA approval from USFDA for Ryaltris™ Nasal Spray
Glenmark's subsidiary, Ichnos Sciences and Almirall enter into an exclusive Licensing Agreement
Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22
Glenmark Pharmaceuticals upgraded to 'BB' on expected maintenance of lower leverage, Outlook Stable
Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination
Glenmark launches Tavulus® for COPD treatment in Spain